In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.
|Articles|October 28, 2014
Breakthroughs in Treatments for Idiopathic Pulmonary Fibrosis
Author(s)Adam Hochron
With the approval of two new drugs for the treatment of IPF, patients who otherwise would have only had lung transplantation as a treatment option now have a new way to improve their quality of life.
Advertisement
With the approval of two new drugs for the treatment of IPF, patients who otherwise would have only had lung transplantation as a treatment option now have a new way to improve their quality of life.
At the 2014 annual meeting of the American College of Chest Physicians in Austin, TX, the drug approvals were a topic of considerable discussion. Steven Nathan, MD, FCCP, discusses some of the advances made and what work remains to help patients with this complex, hard-to-treat condition.
Advertisement
Related to this article
Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.
Colin Church, MBBS, PhD, discusses durable 6MWD and NT-proBNP signals in a TPIP open-label extension and what phase 3 needs to show next.
Colin Church, MBBS, PhD, discusses 24-month open-label extension data showing TPIP remains tolerable in patients with PH-ILD, with no new safety signals.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
VA Dialysis Tied to Lower Mortality, With Virginia Wang, PhD, MSPH
3
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
4
Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding
5